 |
|
Part of drug trial for patients with atrial fibrillation discontinued
September 07, 2005ACTIVE-A and ACTIVE-I to continue
Hamilton, Ontario, Canada-Study treatments for the ACTIVE W trial of the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) program have been discontinued due to a significant difference in efficacy, in favour of the standard oral anticoagulation (OAC) over antiplatelet therapy (clopidogrel plus aspirin).
The ACTIVE trial, the largest randomised international trial program ever conducted in atrial fibrillation (AF), was designed to respond to a largely unmet medical need in the treatment of patients with AF, who are at an increased risk of life-threatening vascular events such as stroke, myocardial infarction and death.
Investigators at 600 sites will adjust their patients' medications and continue to monitor their health. Approximately 3,000 patients worldwide will be affected by the changes in the study.
After an interim analysis of the study, the recommendation of an independent Data Safety Monitoring Board to discontinue the ACTIVE W trial was endorsed by the ACTIVE study steering committee.
The board also recommended two other trials of the ACTIVE program be continued. The study's steering committee agreed with the recommendation to discontinue study treatments for ACTIVE W, and endorsed the recommendation to continue the ACTIVE A (clopidogrel compared with ASA alone), and ACTIVE I (irbesartan to placebo in addition to usual blood pressure lowering therapy).
"In the ACTIVE W trial, most of the patients had been receiving OAC prior to entry into the trial," said SalimYusuf, PhD, chairman of the steering committee for the ACTIVE trial program. "These patients achieved high levels of compliance to OAC in the recommended therapeutic range. In the ACTIVE-W trial, a clear benefit in favour of OAC was evident."
Stuart Connolly, MD, principal investigator of the program, emphasized that: "It is important to continue the ACTIVE A and ACTIVE I parts of the study program to evaluate the potential role which clopidogrel can play in the management of atrial fibrillation patients who are intolerant to oral anticoagulants, and to understand the role of irbesartan in patients with atrial fibrillation."
Clinical guidelines recommend the use of OAC therapy for most patients with atrial fibrillation in order to prevent embolic events. However, OAC therapy is associated with a narrow therapeutic window, requires regular monitoring and is contraindicated in some patients. Aspirin is an option in patients who cannot tolerate OACs. The ACTIVE trial programme is designed to evaluate the appropriate place of clopidogrel plus aspirin in the prevention of embolic events in atrial fibrillation patients.
ACTIVE is a phase III multicenter, multinational clinical development program that includes three trials. In ACTIVE A, clopidogrel plus aspirin is compared with aspirin alone in patients who have a contraindication for OACs or are unwilling to take an OAC, with the hypothesis that clopidogrel plus aspirin would be superior to aspirin. ACTIVE I is evaluating whether the angiotensin II receptor antagonist, irbesartan, is superior to placebo (in addition to usual blood pressure lowering therapy) in preventing vascular events in patients with atrial fibrillation.
The ACTIVE trial program is being conducted at more than 600 sites worldwide in 30 countries.
Atrial fibrillation is the most common chronic cardiac rhythm disturbance and it is responsible for a substantial amount of morbidity, disability and mortality in the general population.
McMaster University
After an interim analysis of the study, the recommendation of an independent Data Safety Monitoring Board to discontinue the ACTIVE W trial was endorsed by the ACTIVE study steering committee.
The board also recommended two other trials of the ACTIVE program be continued. The study's steering committee agreed with the recommendation to discontinue study treatments for ACTIVE W, and endorsed the recommendation to continue the ACTIVE A (clopidogrel compared with ASA alone), and ACTIVE I (irbesartan to placebo in addition to usual blood pressure lowering therapy).
"In the ACTIVE W trial, most of the patients had been receiving OAC prior to entry into the trial," said SalimYusuf, PhD, chairman of the steering committee for the ACTIVE trial program. "These patients achieved high levels of compliance to OAC in the recommended therapeutic range. In the ACTIVE-W trial, a clear benefit in favour of OAC was evident."
Stuart Connolly, MD, principal investigator of the program, emphasized that: "It is important to continue the ACTIVE A and ACTIVE I parts of the study program to evaluate the potential role which clopidogrel can play in the management of atrial fibrillation patients who are intolerant to oral anticoagulants, and to understand the role of irbesartan in patients with atrial fibrillation."
Clinical guidelines recommend the use of OAC therapy for most patients with atrial fibrillation in order to prevent embolic events. However, OAC therapy is associated with a narrow therapeutic window, requires regular monitoring and is contraindicated in some patients. Aspirin is an option in patients who cannot tolerate OACs. The ACTIVE trial programme is designed to evaluate the appropriate place of clopidogrel plus aspirin in the prevention of embolic events in atrial fibrillation patients.
ACTIVE is a phase III multicenter, multinational clinical development program that includes three trials. In ACTIVE A, clopidogrel plus aspirin is compared with aspirin alone in patients who have a contraindication for OACs or are unwilling to take an OAC, with the hypothesis that clopidogrel plus aspirin would be superior to aspirin. ACTIVE I is evaluating whether the angiotensin II receptor antagonist, irbesartan, is superior to placebo (in addition to usual blood pressure lowering therapy) in preventing vascular events in patients with atrial fibrillation.
The ACTIVE trial program is being conducted at more than 600 sites worldwide in 30 countries.
Atrial fibrillation is the most common chronic cardiac rhythm disturbance and it is responsible for a substantial amount of morbidity, disability and mortality in the general population.
McMaster University
Atrial Fibrillation Current Events and Atrial Fibrillation News RSSSize matters: Obesity leading risk factor of left atrial enlargement during aging
Aside from aging itself, obesity appears to be the most powerful predictor of left atrial enlargement (LAE), upping one's risk of atrial fibrillation (the most common type of arrhythmia), stroke and death.
Experts unveil new CVD guidelines and position papers
Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.
Learning the risks for stroke - and taking action
With this theme in mind, the European Society of Cardiology (ESC) emphasises that most of the risks for stroke are also the major risks for coronary heart disease - and thus the object of the ESC's far-reaching prevention programme.
Afib triggered by a cell that resembles a pigment-producing skin cell
The source and mechanisms underlying the abnormal heart beats that initiate atrial fibrillation (Afib), the most common type of abnormal heart beat, have not been well determined.
New blood-thinning drug safer than rat poison
In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as warfarin, but with fewer side effects.
Women with diabetes at increased risk for irregular heart rhythm
Diabetes increases by 26 percent the likelihood that women will develop atrial fibrillation (AF), a potentially dangerous irregular heart rhythm that can lead to stroke, heart failure, and chronic fatigue.
Women with Atrial Fibrillation Are at Significantly Higher Risk of Stroke and Death Compared to Men and Receive Less Attention
Even though the incidence of atrial fibrillation is higher in men than women, a review of past studies and medical literature completed by cardiac experts at Rush University Medical Center shows that women are more likely than men to experience symptomatic attacks, a higher frequency of recurrences, and significantly higher heart rates during atrial fibrillation, which increases the risk of stroke.
Mount Sinai first in nation to ablate atrial fibrillation using new visually-guided balloon catheter
Physicians at The Mount Sinai Medical Center in New York became the first in the U.S. to ablate atrial fibrillation using a visually-guided laser balloon catheter.
Atrial fibrillation: Drugs or ablation?
Atrial fibrillation ablation is one of the fastest growing techniques in cardiology and due to the very high number of patients that might be candidates to this procedure, a significant number of resources will have to be devoted to it to be able to treat them in the following years.
Irbesartan reduces heart failure in patients with quivering heart
Most research in atrial fibrillation (AF) has focused on reducing stroke and other embolic events. Yet heart failure occurs more frequently in AF patients, but has not been the focus of intervention research.
More Atrial Fibrillation Current Events and Atrial Fibrillation News Articles
 |
Atrial Fibrillation: From Bench to Bedside (Contemporary Cardiology) by Andrea Natale (Editor), José Jalife (Editor) Advancements in the treatment and prevention of Atrial Fibrillation are presented in this important new book. Atrial Fibrillation affects approximately 2.5 million individuals in the United States and is projected to affect 15 million individuals by 2050. In Atrial Fibrillation: From Bench to Bedside, the reader is provided with the latest information that is critically important in the daily care and for the potential cure of patients with Atrial Fibrillation. Each chapter deals with a different aspect of Atrial Fibrillation and was authored by internationally recognized experts in the evolving field of cardiac electrophysiology. This book is a single source that provides a multi-perspective look at and approach to Atrial Fibrillation. Because Atrial Fibrillation is so prevalent and... |
 |
Atrial Fibrillation (Home Use) Part of the award winning public television series Healthy Body/Healthy Mind. You know the signs...rapid heart beat... shortness of breath... panic! Sounds like a heart attack, or panic disorder. More often, it is Atrial Fibrillation, an irregular heartbeat disorder than can cause the heart to beat more than 300 times a minute. More than 2 million people have Atrial Fibrillation. Here's what happens: because of a problem with the electrical wiring in the heart, the two small upper chambers, the atria, quiver instead of beating effectively. This quivering causes the discomfort the patient feels, and can cause the blood to pool and clot. If a piece of blood clot leaves the heart and becomes lodged in an artery in the brain, a stroke results. About fifteen percent of strokes occur in people... |
 |
Atrial Fibrillation : My Heart, the Doctors, and Me by E. A. Butler (Author) An Investigative Report by an Inquisitive Patient The author felt compelled to write this story after discovering he had paroxysmal atrial fibrillation. He had little previous experience with personal illnesses. Now he found himself dealing with production line medicine. This experience fostered skepticism, doubts, apprehensions and grave concerns. He discovered he was afflicted with one of the most elusive and complex cardiovascular problems that involves the electrical impulse of the heart. This led him to unleash his investigative experience to find out why more hasn't been done to cure the malady. |
|
Atrial Fibrillation - The Most Common Arrhythmia (Have A Heart Series) Starring: Dr. Gerry Maddoux Directed By: Mark Baer Also With: Dr. Gerry Maddoux (Writer), Mark Baer (Producer) | |
 |
Atrial Fibrillation (Fundamental and Clinical Cardiology) by Peter Kowey (Editor), Gerald Naccarelli (Editor) Filling a gap in the literature, this all-encompassing reference explores the epidemiology, mechanisms, and pathophysiology of atrial fibrillation and compiles the latest diagnostic and treatment practices for patient care. The book summarizes the most recent advances in symptom relief, drug development, device management, and long-term control of heart rhythm abnormalities and reviews the latest studies on the prevention of stroke and other thromboembolic events in patients with valvular and nonvalvular atrial fibrillation. Finally, it offers new strategies to improve the therapy and outcomes of patients suffering from the myriad of complications associated with atrial fibrillation. |
 |
A Practical Approach To Catheter Ablation Of Atrial Fibrillation by Lippincott Williams & Wilkins A Practical Approach to Catheter Ablation of Atrial Fibrillation : A Practical Approach to Catheter Ablation of Atrial Fibrillation Pub Date: April 2008 Product Type: Print Author/s: Hugh Calkins MD; Pierre Jais MD; Jonathan S Steinberg MD Written and edited by expert electrophysiologists, this book is a practical, well-illustrated guide to the most successful techniques for catheter ablation of atrial fibrillation. While other texts address ablation of different arrhythmias, this is the first book to focus specifically on atrial fibrillation.Chapters explain how to establish programs and laboratories for treating atrial fibrillation; use complex imaging modalities and guidance systems; implement a variety of catheter-based ablation strategies, either isolated or in... |
 |
Atrial Fibrillation - The Most Common Arrhythmia (Have A Heart Series) Directed By: Mark Baer Also With: Mark Baer (Producer), Dr. Gerry Maddoux (Writer) * 2 Million people in America have atrial fibrillation. * Advancing age, high blood pressure and diabetes are common causes. * Embolic stroke (clot from the fibrillating left atrium) is the most common complication. This can be largely prevented with anticoagulation. * You can have a normal, healthy lifespan with atrial fibrillation. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
A Practical Approach to Catheter Ablation of Atrial Fibrillation (Practical Approach (Lippincott & Wilkins)) by Hugh Calkins (Editor), Pierre Jais (Editor), Jonathan S Steinberg (Editor) Written and edited by expert electrophysiologists, this book is a practical, well-illustrated guide to the most successful techniques for catheter ablation of atrial fibrillation. While other texts address ablation of different arrhythmias, this is the first book to focus specifically on atrial fibrillation. Chapters explain how to establish programs and laboratories for treating atrial fibrillation; use complex imaging modalities and guidance systems; implement a variety of catheter-based ablation strategies, either isolated or in tandem; monitor the ablated patient's course for complications and arrhythmia recurrence; and manage these problems should they arise. The chapters on lab staffing and equipment, pre-procedure preparation, and post-procedure care will be of special interest to... |
 |
Critical Care Compendium by Mind-Forge Education Services LLC This is a collection of Self Learning Modules and pocket guides. Below are some of the modules and pocket guides in this product. **A quick handy guide to quickly interpret the 12 lead electrocardiogram, identify ischemia, reciprocal changes and to quickly localize a myocardial infarction and involved coronary arteries. **A brief presentation on atrial fibrillation/flutter, optimal monitoring leads, causes and complications related to open heart surgery. **A brief over view of current Advanced Cardiac Life Support treatment algorithms. **ACLS 2006 Code Drugs: Detailed description of 2006 ACLS code drugs and drip charts. (Current for 2007) **A detailed guide to the autonomic nervous system with emphasis placed on parasympathetic and sympathetic involvement and pharmacological... |
|
Atrial Fibrillation - The Most Common Arrhythmia (Have A Heart Series) Starring: Dr. Gerry Maddoux Directed By: Mark Baer Also With: Dr. Gerry Maddoux (Writer), Mark Baer (Producer) |
| © 2009 BrightSurf.com |